关于CXCL16/CXCR6在肿瘤和炎症性疾病中的认识与治疗进展：一项叙述性综述
Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.
摘要(中文译文)
CXCL16/CXCR6轴在包括肿瘤和炎症性疾病在内的多种病理过程中发挥着多方面的双向调控作用。其功能具有显著的背景依赖性，既能够抑制也能够促进疾病进展。本文旨在通过全面综述该轴在不同疾病中的功能谱，系统分析其“双刃剑”特征。首先，我们探讨其在肿瘤微环境中的双向调控机制，重点强调肿瘤异质性的影响以及CXCL16亚型（膜结合型和可溶型）在决定功能结局中的不同作用。随后，我们将讨论扩展至炎症性疾病，考察该轴作为这些疾病预测标志物的潜力，并呈现其在哮喘等疾病中作用的最新见解。此外，我们还综述了针对该轴的药物开发最新进展，并阐明其作用机制。最后，本文强调，准确识别CXCL16/CXCR6轴功能转变的关键节点是靶向治疗开发的核心挑战与机遇。
Abstract
The CXCL16/CXCR6 axis exerts a multifaceted, bidirectional regulatory influence across various pathological processes, including neoplasms and inflammatory disorders. Its functions are notably context-dependent, possessing the capacity to both inhibit and facilitate disease progression. This article aims to systematically analyze this 'double-edged sword' characteristic by providing an exhaustive review of the axis's functional spectrum across different diseases. Initially, we explore its bidirectional regulatory mechanisms within the tumor microenvironment, emphasizing the influence of tumor heterogeneity and the distinct roles of CXCL16 isoforms (membrane-bound and soluble) in determining functional outcomes. Subsequently, we broaden the discussion to encompass inflammatory diseases, examining the axis's potential as a predictive marker in these conditions and presenting the latest insights into its role in diseases such as asthma. Additionally, we provide a review of current advancements in drug development targeting this axis and elucidate its mechanisms of action. Ultimately, the paper underscores that accurately identifying the critical nodes where the CXCL16/CXCR6 axis alters its function is the central challenge and opportunity for the development of targeted therapies.
如何引用
AMA
Xiaohong Li, Shuai Liu, Die Qian, Maokui Huang, Mingmin Na, Qingyan Mo, et al. Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1802735.
APA
Xiaohong Li, Shuai Liu, Die Qian, Maokui Huang, Mingmin Na, Qingyan Mo, et al (2026). Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1802735
GB/T 7714
Xiaohong Li, Shuai Liu, Die Qian, Maokui Huang, Mingmin Na, Qingyan Mo, et al. Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1802735.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出